Welcome to ATHN

Our Top Stories

ATHN Transcends
ATHN Transcends is a natural history cohort study focused on participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendencies. ATHN Transcends provides clinical researchers with a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data to increase knowledge in these important areas of research.
Electronic Informed Consent (eIC) and ATHN 9
ATHN’s new eConsent portal will facilitate and streamline the informed consent process for patients in ATHN studies. The eConsent portal is currently only available for participants enrolling in ATHN 9.

AI/Machine Learning Research Grant
Pfizer has awarded ATHN a grant to research at the provider level hemophilia patients who are at risk for poor outcomes. The proposal will utilize a combination of machine learning and artificial intelligence (AI) to create a predictive model and share that knowledge with ATHN Affiliates. Contact support@athn.org for more information.
ATHNdataset
Researchers rely on data from this vital community resource for a variety of ATHN research projects. Learn more about this safe, secure national database.
ATHN Data Quality Counts
This competitive award is supported by The Hemophilia Alliance, The Alliance Pharmacy, and Indiana Hemophilia & Thrombosis Center and provides funding to enrich the ATHNdataset.

Office of Public Health Initiatives
The ATHN Office of Public Health Initiatives (OPHI) aims to leverage ATHN’s capabilities to support medically underserved populations by strengthening our partnerships throughout the blood disorders community. We’re working to establish a Health Equity Program, expand ATHN’s focus on sickle cell disease, and more.